Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | PAM | P19021 | 2/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.50 |
| ▸ | PPARG | P37231 | 6/20 | 0.50 |
| ▸ | PPARD | Q03181 | 6/20 | 0.50 |
| ▸ | PPARA | Q07869 | 6/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4651569 | 1.00 | CES2 (0.69) | CES2EPHX2PAMPLA2G4BGPR84 | |
| SCHEMBL7249862 | 1.00 | CES2 (0.69) | CES2EPHX2PAMPLA2G4BGPR84 | |
| SCHEMBL8198788 | 1.00 | CES2 (0.69) | CES2EPHX2PAMPLA2G4BGPR84 | |
| SCHEMBL501889 | 1.00 | CES2 (0.69) | CES2EPHX2PAMPLA2G4BGPR84 | |
| SCHEMBL1603697 | 1.00 | CES2 (0.69) | CES2EPHX2PAMPLA2G4BGPR84 | |
| SCHEMBL21611691 | 1.00 | CES2 (0.69) | CES2EPHX2PAMPLA2G4BGPR84 | |
| SCHEMBL3296171 | 1.00 | CES2 (0.69) | CES2EPHX2PAMPLA2G4BGPR84 | |
| SCHEMBL8626082 | 1.00 | CES2 (0.69) | CES2EPHX2PAMPLA2G4BGPR84 | |
| SCHEMBL21611665 | 1.00 | CES2 (0.69) | CES2EPHX2PAMPLA2G4BGPR84 | |
| SCHEMBL7611940 | 1.00 | CES2 (0.69) | CES2EPHX2PAMPLA2G4BGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | EPITRACKER INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | Epitracker, Inc. (US) | 2025-10-14 | — | — | US | disclosed |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-116770068-A | Efficient aluminum solvent extraction system | 中国科学院过程工程研究所 | 2023-09-19 | — | — | CN | disclosed |
| EP-3934639-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| WO-2020204662-A1 | DONEPEZIL MYRISTYLOXYMETHYL ETHER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-10-08 | — | — | WO | disclosed |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3275973-B1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORP (JP) | 2019-12-18 | — | — | EP | disclosed |
| EP-2910547-B1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | UNIV OKAYAMA (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9512075-B2 | Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug | OKAYAMA UNIVERSITY (JP) | 2016-12-06 | — | — | US | disclosed |
| US-9512075-B2 | Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug | OKAYAMA UNIVERSITY (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20150291523-A1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150291523-A1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-2910547-A1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | Okayama University (JP) | 2015-08-26 | — | — | EP | disclosed |
| EP-1099698-A1 | Macrocyclic oxalactones ( dioxacycloalkan-ones ) and their use as perfumes | PFW AROMA CHEMICALS B.V. (NL) | 2001-05-16 | — | — | EP | disclosed |
| EP-0488982-A1 | Rubber compositions having improved processability and improved rubber-vulcanisate properties | MONSANTO EUROPE S.A./N.V. (BE) | 1992-06-03 | — | — | EP | disclosed |
| EP-0487809-A1 | Rubber compositions having improved processability and improved rubber-vulcanisate properties | MONSANTO EUROPE S.A./N.V. (BE) | 1992-06-03 | — | — | EP | disclosed |
| US-4110073-A | COMBINATION OF ANION-ACTIVE DISPERSING AGENTS | CIBA-GEIGY AG (CH) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | SCD, FABP7, ELOVL1 | CES2 205/4885EPHX2 1687/4885PAM 1815/4885 |
| US-20150291523-A1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | FURIN, ACE, SHARPIN | CES2 2525/4885EPHX2 1089/4885PAM 541/4885 |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | CES2 1954/4885EPHX2 3189/4885PAM 2295/4885 |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | CES2 1954/4885EPHX2 3189/4885PAM 2295/4885 |
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | CNR1, CNR2, FFAR1 | CES2 133/4885EPHX2 1451/4885PAM 2850/4885 |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | SCD, FABP7, ELOVL1 | CES2 205/4885EPHX2 1687/4885PAM 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.